POSTED: November 14, 2014

NEW YORK CITY, November 14, 2014 – - Zocere, Inc., a New Mexico-based pharmaceutical company developing a biologic-based neuroprotectant drug for ischemic stroke, will be presenting at Investing for Cures: 2020 Foresight in New York Wednesday, November 19.

Hosted by Greenwich, Connecticut-based Landmark Angels, a private angel investment group, Investing for Cures brings together major leaders in the intersecting worlds of philanthropy, foundation, pharmaceuticals, family offices, high net worth investors, and prominent therapeutic, device, and digital IT companies. Participants explore the changing parameters and transformative innovations occurring in health care. Industry leaders will discuss how they expect this landscape to unfold and their path to 2020.

Landmark Angels invests in companies with strong and experienced management teams and that possess large, definable markets and “must have” or disruptive products.

Zocere CEO Wayne Laslie has more than 30 years of experience in pharmaceutical commercialization in U.S. and international markets. He believes his company’s drug, which protects the brain post stroke, is the transformative technology the healthcare industry and investors seek. “People can relate to stroke as it touches so many lives. Each year there are an estimated 750,000 acute ischemic strokes in the United States and more than two million worldwide. Only three to five percent of stroke victims receive pharmacologic treatment because of risks associated with current therapies. Our drug candidate has the potential to become the first neuroprotectant on the market.”

Zocere’s drug is based on a STEP protein, a cell-permeable, recombinant peptide, that shows promise as a potent “brain saving” drug when administered post stroke. It also holds the potential for treating other brain trauma, including concussion. Zocere has exclusive, global rights to the patent-pending technology, which it licensed from the University of New Mexico. Zocere has succeeded in raising a half million dollars, and is seeking a capital investment of $1 million to $1.5 million in exchange for equity in the company. These funds will further development up to the Investigational New Drug (IND) process.